1.28 Questionable FDA Drug Approvals and Building a Career with Dr. Chadi Nabhan
In this episode we critique two recent FDA drug a…
Plenary Session - inactive due to federal service · Plenary Session - inactive due to federal service
December 13, 20181h 4mExplicit
Audio is streamed directly from the publisher (feeds.soundcloud.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode we critique two recent FDA drug approvals (venetoclax in combination with azacitidine or decitabine or low-dose cytarabine; glasdegib in combination with low-dose cytarabine -- both for acute myeloid leukemia)and we interview Dr. Chadi Nabhan, the Chief Medical Officer of Cardinal Health, on career transitions. The interview was taped on location at the 2018 annual conference of the American Society of Hematology in San Diego.
Topics
medicineoncologyhealthpolicy